DOJ Urges Judges to Dismiss Abortion Drug Lawsuits from Republican States
On Monday, the Department of Justice, under the Trump administration, called on judges to reject attempts by three Republican-led states to restrict access to abortion medications.
Currently, the stance of the DOJ appears to align with the Biden administration’s position. The District Court for the Northern District of Texas suggested that the lawsuit should not proceed there, indicating that challenges from Missouri, Kansas, and Idaho lack proper venue.
According to the states, their claims do not connect to the Northern District of Texas. They argued that if they pursued their own lawsuit in that district, it wouldn’t be viable because of venue issues.
In its filing, the DOJ pointed out that the ongoing litigation had no justification. The DOJ noted that the original plaintiffs seeking to contest the FDA’s decisions had been dismissed by the Supreme Court, which ruled that these plaintiffs lacked standing to pursue the case.
Earlier this year, the Supreme Court stated that the Physicians and Life Support Associations, which initiated the original challenge, did not have standing. This ruling came as a significant decision in the abortion medication debate.
Additionally, the Biden administration previously indicated that these state lawsuits should either be dismissed or moved to a different venue. Judge Matthew Caxmalick permitted these cases to continue in January.
The states argued that FDA regulations purportedly allowed individuals to bypass state laws. However, the DOJ countered this, asserting that the potential for someone to violate state law had not caused any harm to the government.
The DOJ concluded that since the original plaintiffs were found to lack standing and had voluntarily withdrawn their claims, the states’ claims should also have no bearing on the current district. They advised that the claims could be pursued in a more appropriate venue.
Recent research released by the Center for Ethics and Public Policy revealed that adverse events linked to mifepristone, an abortion medication, were significantly higher than what was documented on drug labels. The study found that nearly one in ten women using the drug experienced serious adverse effects within 45 days.
